- Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development
- The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT
- It will focus on the psychedelics industry, showcasing the latest research and development within the sector
- Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline
In an official statement dated June 24, 2021,
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development.
The virtual event, scheduled on Wednesday, July 7, 2021, from 11:50 a.m. to 12:50 p.m. EDT, will focus on the psychedelics industry, mainly showcasing the latest research and development within the sector (
https://ibn.fm/cihuB). The event is also intended to expand businesses currently looking for capital, mainly by directly delivering the industry’s most promising opportunities to funds and investors.
The July 7 event marks the second global psychedelics industry investment event that solely focuses on research and development. As has been the case with the previous events, this one is meant to showcase the latest clinical evidence for this promising sector. It will feature a concise half-day program, with provisions for interactions with industry leaders, global psychedelics investors and rising entrepreneurs (
https://ibn.fm/QN5e7).
Tryp Therapeutics is a pharmaceutical enterprise committed to developing bioscience solutions for conditions with unmet needs (
https://ibn.fm/VFGjr). Its current flagship program involves developing a synthetic psychedelic drug candidate specifically designed to treat particular pain and eating disorder indications. Its trademarked Psilocybin-for-Neuropsychiatric Disorder (“PFN”) program is the basis for the company’s development of treatments for several diseases that lack effective treatment options (
https://ibn.fm/Ol6Tb).
At this Psych Investor Summit, Tryp Therapeutics, through its Chairman and Chief Executive Officer, Mr. Greg McKee, will share the strides that it has made so far. More specifically, Mr. McKee will delve into more detail on Tryp’s drug development pipeline and what it is doing to push the envelope regarding the use of psychedelics to treat specific types of pain and diseases (
https://ibn.fm/zZu5V).
Mr. McKee will also contribute to a panel discussion on the future of research and development and the development activities for psychedelic drug compounds. Other speakers presenting at the conference include Rick Doblin, the Founder and Executive Director of MAPS; Christian Angermayer, the Founder of atai Life Sciences; and Dr. Ben Sessa, the Chief Medical Officer at Awkn Life Sciences.
For more information, visit the company’s website at
www.TrypTherapeutics.com. Should you wish to attend the summit, you can register at
www.Psych.Global/agenda/.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at
https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates
PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit
https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW?
Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the
InvestorBrandNetwork.